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MULTI-CENTER REGISTRY OF PERCUTANEOUS CORONARY ROTATIONAL 
ABlATION USING THE ROTABLATOR. 
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an Fourrier, Martin Leon, University of California 
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Prom January 1988 to 1990, 315 patients with 366 
lesions were entered a multi-center study o 
Percutaneous Coronary Rotational Ablation (QTC 
the Rotablator (R) (Heart Technology, Inc.). R is a 
high speed (160-190.000 rpm) rotational catheter with a 
diamond microcrystal tip which ablates inelastic 
atherosclerotic plaque while sparing normal elastic 
tissue. There were 249 males and 66 females with an 
average age of 61 (33-87). Lesions were located in the 
LAD/DIAG 45%. RCA/PDA 36%, CX/OM 16% and lH 3%. Of all 
lesions, 87% were complex (type B or C). Acute success 
defined as <SO% residual stenosis was achieved in 95% of 
patients. Adjunctive PTCA was performed in 32% of 
lesions primarily to achieve maximal luminal diameter in 
larger arteries. Clinically significant complications 
include non-Q MI in 4.8% urgent CABG in 1.6% and Q-wave 
MI in 0.9%. There were no deaths. Long term (> 6 
months) angiographic follow-up was performed in 94% of 
eligible patients (152/162) showing a restenosis rate 
(defined as < 50% residual stenosis at the treatment 
site) of 32%. 
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ic therapy deemed effectfve by 
electrophysiologic testing (EPT) has been reported to 
Qroduce better l-2 year survival in patients with 
inducfble sustained monomotphfc ventricular tachycardia 
(VT); longer follow-up has not been reported. We 
therefore followed all patients with heart disease and 
VT studied ae our institution before 1985. Charts were 
er ejection fraction. Sudden 
Ceath free su s also greater (pe.001) and 
continued to 
when ET was continued. 
had an effective response at EQT and who then died 
suddenly showed 3 hsd subtherapeutic drug levels and 2 
stopped therapy prior to death. Conclusion: An 
sponse to therapy determined by EPT 
proved sudden and all cause of death free 
over 7 years if effective therapy was 
cant inued. Patients with an effective response at EPT 
may still be at risk for sudden death if drug levels 
become subtherapeutic. 
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We hypothesized that electrophysiologic study (EPS) guided suppression 
of ventricular tachycardia (VT) of cycle length+< 250 ms does not predict 
subsequent efficacy. We analyzed 8rZ consecut)ve patients who had sus- 
tained monomorphic VT induced at baseline EPS. patients had an average 
of I .6 follow up EPS drug trials. Thirty-one patients (Group I) had a VT 
cycle length < to 250 ms. Fifty-three patients (Group II) had a VT cycle 
leng’h + 250 ms. age - 63 years, mean ejection fraction - 31%. and 
frequency of car artery disease - 90% were similar in Groups I and 
II. Patients were followed an average of 17 months after EPS. Subsequent 
arrhythmic events were defined as sudden cardiacdeath, documented sus- 
tained VT, syncope. or symptomatic automatic implantable cardioverter 
defibrillator discharge. In Group 1, subsequent arrhythmic events occur- 
red in 6 of 13 patients with successful EPS guided drug therapy compared 
with 6 of 18 patients without successful EPS guided drug therapy (P = 
NS). In Group II, subsequent arrhythmic events occurred in 1 of 13 
patients with successful EPS guided therapy compared with 19 of 41 
patients without successful EPS guided drug therapy (p, = .03). 
CONCLWSlONS Successful EPS guided drug therapy 
able long-term outcome in those patients with a VT c 
250 ms. k~ those patients with a VT cycle length 5 250 ms, successful EPS 
guided drug therapy did not predict an arrhythmia-free long-term 
Conclusion: QTCRA is a safe and effective treatment outcome. 
modality with 
term patency. 
excellent initial results and good long 
